A recent case study sheds new light on the role of brain immune mechanisms in long COVID . The study, the first of its kind, documents rapid and sustained clinical improvement following a single dose of perispinal etanercept (PSE) in an individual with severe long COVID.
Etanercept is an immune modulator that rapidly neutralizes elevated circulating levels of a proinflammatory cytokine, tumor necrosis factor (TNF); perispinal administration is designed to facilitate delivery of etanerceptto the central nervous system, including the brain . Etanercept has been widely used as a chronic treatment for immune-mediated disease, such as rheumatoid arthritis and psoriasis, for more than 20 years.
Standardized instruments were utilized to measure and quantitate the response to PSE, including Grip Strength, Beck Depression Inventory-II; Fatigue Assessment Scale; Trail Making Test, Parts A and B; Controlled Oral Word Association Test; Montreal Cognitive Assessment; Mini-Mental State Examination; Timed Finger-to-Nose Test; 20-meter Self-Paced Walk Test; and the 5 Times Sit-to-Stand Test. Following PSE there was rapid improvement in all clinical measures. The case report contains a detailed description of the clinical history, the response to treatment, and a thorough scientific discussion .
Brain dysfunction caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may extend for months after infection has resolved [3,4]. Intractable cognitive dysfunction, depression, and fatigue are cardinal features of long COVID, a post-viral syndrome also named, variously, post-COVID syndrome, post-acute sequelae of SARS-CoV-2 infection, or post-Covid-19 condition [3,4]. In contrast to acute infection, there is no specific pharmacological or non-pharmacological intervention that is universally recognized as being effective for long COVID . A central role of neuroinflammation in the pathogenesis of long COVID was suggested by increasing clinical evidence and is the subject of intense current interest [3-19].
The potential of etanercept to ameliorate the damaging cytokine storm induced by SARS coronavirus infection was first proposed in 2004 . Increasing evidence documents neuroinflammation following SARS-CoV-2 infection [10,15,18,19,21-28]. Neuroinflammation is increasingly recognized as a cause of chronic brain dysfunction; for example, accumulating evidence documents the existence of chronic neuroinflammation after stroke, with widespread microglial activation [29,30].
Activated microglia secrete TNF, and TNF results in microglial activation, resulting in a feed-forward autocrine loop that may perpetuate deleterious neuroinflammation [31-34]. Perispinal etanercept has previously been reported to produce rapid and sustained improvement in cognition, fatigue, sensation, central post-stroke pain, taste, smell, vision, and hearing in individuals with chronic stroke [2,35-38]. Etanercept, by rapidly neutralizing excess TNF, which functions as a neuromodulator, is thought to improve synaptic, circuit, and network function in the brain [2,36,37,39]. The similarities of the rapid neurological effects of perispinal etanercept in long COVID and chronic stroke are striking and suggest brain neuroinflammation, with microglial activation and elevation of TNF, is a shared pathophysiologic mechanism that is of central importance in both conditions.
Clinical trials will be necessary to further define the response to treatment and to establish optimal dose levels, dosing intervals, duration of response to treatment and safety in larger populations. Nevertheless, the clinical response documented in the case study, quantitated using standard and widely used measures, suggests that long COVID involves perturbed brain immune mechanisms that are at least partially reversible. Furthermore, the clinical response documented in the case study suggests that these perturbed brain immune mechanisms are a viable target for therapeutic intervention and merit further investigation.
Tobinick E, Spengler RN, Ignatowski TA, et al. Rapid improvement in severe long COVID following perispinal etanercept. Curr Med Res Opin. 2022;38(12):2013-2020.
Tobinick E. Perispinal etanercept advances as a neurotherapeutic. Expert Rev Neurother. 2018 Jun;18(6):453-455.
Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022 Apr;22(4):e102-e107.
Group P-CC. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022 Apr 22.
Acosta-Ampudia Y, Monsalve DM, Rojas M, et al. Persistent Autoimmune Activation and Proinflammatory State in Post-COVID Syndrome. The Journal of infectious diseases. 2022 Jan 25.
Braga J, Lepra M, Kish S, et al. Neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms. JAMA Psychiatry. 2023;May 31:e231321. doi:10.1001/jamapsychiatry.2023.1321.
Clark IA. Chronic cerebral aspects of long COVID, post-stroke syndromes and similar states share their pathogenesis and perispinal etanercept treatment logic. Pharmacol Res Perspect. 2022 Apr;10(2):e00926.
Durstenfeld MS, Peluso MJ, Kaveti P, et al. Inflammation during early post-acute COVID-19 is associated with reduced exercise capacity and Long COVID symptoms after 1 year. medRxiv. 2022 Jun 1.
Frank MG, Fleshner M, Maier SF. Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19. Brain Behav Immun. 2023;111:259-269.
Frank MG, Nguyen KH, Ball JB, et al. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties. Brain Behav Immun. 2022 Feb;100:267-277.
Kavanagh E. Long Covid brain fog: a neuroinflammation phenomenon? Oxford Open Immunology. 2022;3(1):iqac007.
Peluso MJ, Lu S, Tang AF, et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. The Journal of infectious diseases. 2021 Dec 1;224(11):1839-1848.
Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022 Feb;23(2):210-216.
Schwabenland M, Salie H, Tanevski J, et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity. 2021 Jul 13;54(7):1594-1610 e11.
Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022 Jan 21;375(6578):267-269.
Tate W, Walker M, Sweetman E, et al. Molecular Mechanisms of Neuroinflammation in ME/CFS and Long COVID to Sustain Disease and Promote Relapses. Frontiers in Neurology. 2022;13(article 877772).
Thakur KT, Miller EH, Glendinning MD, et al. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021 Oct 22;144(9):2696-2708.
Zhou Y, Xu J, Hou Y, et al. Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. bioRxiv. 2021 Mar 22.
Tobinick E. TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr Med Res Opin. 2004 Jan;20(1):39-40.
Matschke J, Lutgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020 Nov;19(11):919-929.
Almutairi MM, Sivandzade F, Albekairi TH, et al. Neuroinflammation and Its Impact on the Pathogenesis of COVID-19. Front Med (Lausanne). 2021;8:745789.
Dale RC, Mohammad SS, Britton PN. Neuroinflammation triggered by SARS-CoV-2 infection: syndromes and therapies. Lancet Child Adolesc Health. 2021 Sep;5(9):607-609.
Klein R, Soung A, Sissoko C, et al. COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis. Res Sq. 2021 Oct 29.
Lempriere S. Single-cell transcriptomics reveals neuroinflammation in severe COVID-19. Nat Rev Neurol. 2021 Aug;17(8):461.
Sriwastava S, Tandon M, Podury S, et al. COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2. J Neurol. 2021 Dec;268(12):4448-4478.
Yang AC, Kern F, Losada PM, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021 Jul;595(7868):565-571.
Schaechter JD, Hightower BG, Kim M, et al. A pilot [(11)C]PBR28 PET/MRI study of neuroinflammation and neurodegeneration in chronic stroke patients. Brain Behav Immun Health. 2021 Nov;17:100336.
Shi K, Tian DC, Li ZG, et al. Global brain inflammation in stroke. Lancet Neurol. 2019 Nov;18(11):1058-1066.
Kuno R, Wang J, Kawanokuchi J, et al. Autocrine activation of microglia by tumor necrosis factor-alpha. J Neuroimmunol. 2005 May;162(1-2):89-96.
Raffaele S, Lombardi M, Verderio C, et al. TNF Production and Release from Microglia via Extracellular Vesicles: Impact on Brain Functions. Cells. 2020 Sep 23;9(10).
Riazi K, Galic MA, Kuzmiski JB, et al. Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17151-6.
Takeuchi H, Jin S, Wang J, et al. Tumor Necrosis Factor-alpha Induces Neurotoxicity via Glutamate Release from Hemichannels of Activated Microglia in an Autocrine Manner. J Biol Chem. 2006;281(30):21362-21368.
Tobinick E. Immediate Resolution of Hemispatial Neglect and Central Post-Stroke Pain After Perispinal Etanercept: Case Report. Clin Drug Investig. 2020 Jan;40(1):93-97.
Tobinick E, Kim NM, Reyzin G, et al. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs. 2012 Dec;26(12):1051-70.
Tobinick E. Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs. 2011 Feb;25(2):145-55.
Ralph SJ, Weissenberger A, Bonev V, et al. Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation. Expert Opin Investig Drugs. 2020 Mar;29(3):311-326.
Ignatowski TA, Spengler RN, Dhandapani KM, et al. Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs. 2014 Aug;28(8):679-97.
Edward Tobinick MD, Director, Institute of Neurological Recovery; Boca Raton, FL, USA; Contact information: firstname.lastname@example.org Telephone: 561.353.9707; Fax: 561.372.7874
Robert N. Spengler, PhD, Executive Director, Brain-Body Research Institute, Lancaster, NY, USA. Contact information: email@example.com Telephone: 716.683.4939.
Tracey A. Ignatowski, PhD, Assistant Professor, University at Buffalo-SUNY, Jacobs School of Medicine and Biomedical Sciences, Department of Pathology and Anatomical Sciences, 955 Main Street, Buffalo, NY, USA. Contact information: firstname.lastname@example.org Telephone: 716.829.3102; Fax: 716.829.2725
Dr. Tobinick is the inventor of multiple issued U.S. and international patented treatment methods involving the use of etanercept, including methods of perispinal administration and related devices, for treatment of neurological disorders, and utilizes perispinal etanercept in his medical practice, the Institute of Neurological Recovery, in Boca Raton, Florida.